Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level <...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiong, Ing S., Dillon, Richard, Ivey, Adam, Kuzich, James A., Thiagarajah, Nisha, Sharplin, Kirsty M., Kok, Chung Hoow, Tedjaseputra, Aditya, Rowland, James P., Grove, Carolyn S., Abro, Emad, Shortt, Jake, Hiwase, Devendra K., Bajel, Ashish, Potter, Nicola E., Smith, Matthew L., Hemmaway, Claire J., Thomas, Abin, Gilkes, Amanda F., Russell, Nigel H., Wei, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153038/
https://www.ncbi.nlm.nih.gov/pubmed/34555849
http://dx.doi.org/10.1182/bloodadvances.2021005455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153038/
https://www.ncbi.nlm.nih.gov/pubmed/34555849
http://dx.doi.org/10.1182/bloodadvances.2021005455

Ejemplares similares